## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -10.2% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($58.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |
| 2025-11-18 | Wolfe Research | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |
| 2025-11-18 | Wolfe Research | init | Peer Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 9 ($2.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. High short interest (15.2%, 7.7 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 242% YoY. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.0B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 15.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -13.3% to -10.2% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 14.2pp (needs >4.0% for momentum thesis). AM_20 at -10.3% indicates price below own 20MA trend. Underperforming sector by 11.7pp, stock-specific weakness. Below SMA200 (0.95x), long-term trend not supportive. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -10.25% (CS: 2) | Weak |
| RSI_14 | 35.7 | Neutral |
| MACD Histogram | -0.21 | Bearish |
| vs SMA20 | 0.897x | Below |
| vs SMA50 | 0.825x | Below |
| vs SMA200 | 0.954x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $68.34
- **Stop Loss:** $58.62 (14.2% risk)
- **Target:** $78.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 123
- **Position Value:** $8,405.82
- **Portfolio %:** 8.41%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*